This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Review of bupivacaine use in treatment of strabismus

Review of bupivacaine use in treatment of strabismus
Reviewed by Fiona Rowe

5 June 2023 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus
Share This

This review aimed to assess the applications of bupivacaine (B) in the non-surgical treatment of strabismus in human and animal studies. Animal studies show that singly-innervated fibres with low concentrations of mitochondria and developed sarcoplasmic reticulum are more affected by B and are noted in the global muscle layer. Satellite cells are preserved and activate and proliferate during muscle regeneration. On this basis, B acts to increase muscle strength. Human studies show initial weakness in muscle function after injection followed by improvement in eye movement and consequent reduction in deviation of prior treated strabismus cases. Muscle size increases in volume on imaging. It has been used in conjunction with botulinum toxin (BT) with a correction rate about twice of B alone. There is no effect difference for exotropia vs esotropia but better success for deviations <25PD. Injection has been done with and without EMG guidance. Muscle weakness starts within minutes of injection and lasts up to one week. Muscle regeneration is over 34 weeks. If used with BT, often no change is seen in the first two weeks. Correction rate is 5-8PD with B alone and about 15PD when combined with BT. This is a promising treatment but with considerable limitations such as the need for direct infusion of relatively large volumes of B.

Applications of bupivacaine in the non-surgical treatments of strabismus: a review.
Kiarudi MY, Shahri SHG, Es’hahi A, et al.
STRABISMUS
2022;30(3):204-8.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency